LAMISIL
LOE ApproachingNDAORALTABLET
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMISIL is an oral antifungal tablet approved in 1996 for systemic fungal infections. The drug is a small-molecule compound developed by Novartis. Its specific indication and mechanism of action are not detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), requiring focus on lifecycle extension or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
30 enrolled
Candidiasis, OralHIV Infections
Career Relevance
LAMISIL offers limited near-term career growth given approaching LOE and no linked job openings. This role is best suited for professionals managing mature products or preparing for market transitions.
Brand Manager
Worked on LAMISIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.